Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis.

Vania Tietsche de Moraes HungriaDeborah M Martínez-BañosMaría-Victoria MateosMeletios A DimopoulosMichele CavoBart HeegAndrea GarciaAnnette LamGerardo MachnickiJianming HeMariana Fernandez

Published in: Advances in therapy (2020)

In transplant-ineligible patients with NDMM, D-VMP showed superior effectiveness versus bortezomib- and thalidomide-based regimens, supporting adoption of daratumumab-containing regimens in Latin America.

Keyphrases

multiple myeloma
newly diagnosed
healthcare
randomized controlled trial
high dose
palliative care
systematic review
quality improvement
low dose